FDA Approves TYENNE — Fresenius Kabi USA, LLC

Fresenius Kabi USA announced on March 14, 2025, the FDA approval of its biosimilar TOCILIZUMAB (TYENNE), a fully human monoclonal antibody for injection. This approval introduces a potential competitive alternative to key biologics in the rheumatology market, addressing the needs of patients switching from originators and expanding access to injectable anti-IL-6R therapies.